万方数据
万方数据
万方数据
银屑病的生物治疗新进展
作者：李红， 周澜华， LI Hong， ZHOU Lan-hua
作者单位：李红,LI Hong(天津市长征医院,天津,300021)， 周澜华,ZHOU Lan-hua(空军航空医学研究所附属医院,北京,100089)
刊名：
中国皮肤性病学杂志
英文刊名：THE CHINESE JOURNAL OF DERMATOVENEREOLOGY
年，卷(期)：2010,24(9)
1.Berger JR;Houff SA;Major EO Monoclonal antibodies and progressive multifocal leukoencephalopathy 2009(06)
2.Leonardi C;Menter A;Hamilton T Efalizumab:results of a 3-year continuous dosing study for the
long-term control of psoriasis 2008(05)
3.Griffiths CE The immunological basis of psoriasis 2003(Suppl 2)
4.Goffe B;Papp K;Gratton D An integrated analysis of thirteen trials summarizing the long-term
safety of alefacept in psoriasis patients who have received up to nine courses of therapy[外文期刊] 2005(12)
5.Krueger GG;Papp KA;Stough DB A randomized,double-blind,placebo-controlled phase Ⅲ study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis[外文期刊] 2002(06)
6.Lebwohl M;Christophers E;Langley R An international,randomized,doubleblind,placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis 2003(06)
7.Panayi GS Immunology of psoriasis and psoriatic arthritis 1994(02)
8.Di Cesare A;Di Meglio P;Nestle FO The IL-23/Th17 axis in the immunopathogenesis of psoriasis
2009(06)
9.Austin LM;Ozawa M;Kikuchi T The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines,interferon-gamma,interleukin-2,and tumor necrosis factor-alpha,defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients 1999(05)
10.Sfikakis PP The first decade of biologic TNF antagonists in clinical practice:lessons
learned,unresolved issues and future directions 2010
11.Leonardi CL;Kimball AB;Papp KA Efficacy and safety of ustekinumab,a human interleukin-12/23 monoclonal antibody,in patients with psoriasis:76-week results from a randomised,double-
blind,placebo-controlled trial 2008(9625)
12.Krueger GG;Langley RG;Leonardi C A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis 2007(06)
13.Mossner R;Reich K Management of severe psoriasis with TNF antagonists.Adalimumab,etanereept and infliximab 2009
14.Tyring S;Gottlieb A;Papp K Etanercept and clinical outcomes,fatigue,and depression in
psoriasis:double-blind placebo-controlled randomised phase Ⅲ trial[外文期刊] 2006(9504)
15.Papp KA;Tyring S;Lahfa M A global phase Ⅲ randomized controlled trial of etanercept in psoriasis:safety,efficacy,and effect of dose reduction[外文期刊] 2005(06)
16.Papoutsaki M;Chimenti MS;Costanzo A Adalimumab for severe psoriasis and psoriatic arthritis:an open-label study in 30patients previously treated with other biologics[外文期刊] 2007(02)
17.Menter A;Tyring SK;Gordon K Adalimumab therapy for moderate to severe psoriasis:A
randomized,controlled phase Ⅲ trial 2008(01)
18.Gordon KB;Langley RG;Leonardi C Clinical response to adalimumab treatment in patients with moderate to severe psoriasis:double-blind,randomized controlled trial and open-label extension study [外文期刊] 2006(04)
19.Antoniou C;Stefanaki Ⅰ;Stratigos A Infliximab for the treatment of psoriasis in Greece:4 years
of clinical experience at a single centre 2010(05)
20.Reich K;Nestle FO;Papp K Infliximab induction and maintenance therapy for moderate-to-severe psoriasis:a phase Ⅲ,multicentre,double-blind trial[外文期刊] 2005(9494)
21.Greaves MW;Weinstein GD Treatment of Psoriasis 1995(09)
本文链接：/Periodical_zgpfxbxzz201009030.aspx。